Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94103Research ArticleSovremennye podkhody k diagnostike i lecheniyu osteoporozaPigarovaE. A-RozhinskayaL. Ya-15042014164828728122021Copyright © 2014, Consilium Medicum2014остеопорозминеральная плотностькостная тканьрезорбцияантирезорбтивные препаратыбифосфонаты[Osteoporosis Facts and Statistics. URL: http://www.osteoporosis.ca/index.php/ci_id/8867/la_id/1.htm][Wiktorowicz M.E, Goeree R, Papaioannou A et al. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 2001; 12: 271-8. Doi: 10.1007/s001980170116.][Cauley J.A, Hochberg M.C, Lui L.Y et al. Long - term risk of incident vertebral fractures. JAMA 2007; 298: 2761-7. Doi: 10.1001/jama.298.23.2761.][Dennison E, Cole Z, Cooper C. Diagnosis and epidemiology of osteoporosis. Curr Opini Rheumatol 2005; 17: 456-61.][Watts N.B, Adler R.A, Bilezikian J.P et al; Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012, 97 (6): 1802-22.][Ward K.A, Roberts S.A, Adams J.E, Mughal M.Z. Bone geometry and density in the skeleton of pre - pubertal gymnasts and school children. Bone 2005; 36 (6): 1012-8.][Rao S.S, Budhwar N, Ashfaque A. Osteoporosis in men. Am Fam Physician 2010; 82 (5): 503-8.][Ebeling P.R. Osteoporosis in Men. N Engl J Med 2008; 358: 1474-82.][Das S, Crockett J.C. Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther 2013; 31 (7): 435-48. Doi: 10.2147/DDDT.S31504.][Ralston S.H, Uitterlinden A.G. Genetics of osteoporosis. Endocr Rev 2010; 31 (5): 629-62.][Melton 3rd L.J, Atkinson E.J, O’Connor M.K et al. Bone density and fracture risk in men. J Bone Miner Res 1998; 13: 1915-23.][Kanis J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994; 4 (6): 368-81.][National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008.][Lewiecki E.M, Bilezikian J.P, Bonewald L et al. Osteoporosis Update: Proceedings of the 2013 Santa Fe Bone Symposium. J Clin Densitom. 2014 Mar 7. Pii: S1094-6950(13)00214-X. Doi: 10.1016/j.jocd.2013.11.006.][Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev 2008; 29 (4): 441-64.][Скрипникова И.А., Рожинская Л.Я. Применение дженериков - способ повышения приверженности лечению остеопороза. Остеопороз и остеопатии. 2010; 3: 37-41.][Рожинская Л.Я., Дзеранова Л.К., Марова Е.И. и др. Результаты лечения постменопаузального остеопороза бисфосфонатом фосамаксом (алендронатом). Остеопороз и остеопатии. 1998; 2: 28-32.][Black D.M, Cummings S.R, Karpf D.B et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention Trial Research Group. Lancet 1996; 348: 1535-41.][Curtis J.R, Westfall A.O, Cheng H et al. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101.038 new bisphosphonate users. J Bone Miner Res 2008; 23 (9): 1435-41.][Siris E.S, Harris S.T, Rosen C.L et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clinic Proc 2006; 81: 1013-22.][Лялина В.В., Мылов Н.М., Дмитриева Е.Г. и др. Изучение переносимости алендроната 70 мг в неделю и причин отмены лечения у больных постменопаузальным остеопорозом в условиях реальной клинической практики. Остеопороз и остеопатии. 2007; 3: 31-5.][Diez-Perez A, Adachi J.D, Agnusdei D et al; IOF CSA Inadequate Responders Working Group. Treatment failure in osteoporosis. Osteoporos Int 2012; 23 (12): 2769-74. Doi: 10.1007/s00198-012-2093-8. Epub 2012 Jul 27.][Cairoli E, Eller-Vainicher C, Ulivieri F.M et al. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis. Osteoporos Int 2014; 25 (4): 1401-10. Doi: 10.1007/s00198-014-2619-3. Epub 2014 Feb 8.][Плещева А.В., Пигарова Е.А., Дзеранова Л.К. Витамин D и метаболизм: факты, мифы и предубеждения. Ожирение и метаболизм. 2012; 2: 33-42.][Holick M.F, Binkley N.C, Bischoff-Ferrari H.A et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96 (7): 1911-30.]